9 Meters Biopharma Inc.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is de… Read more
Market Cap & Net Worth: 9 Meters Biopharma Inc. (NMTRQ)
9 Meters Biopharma Inc. (PINK:NMTRQ) has a market capitalization of $1.45K ($1.45K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #47722 globally and #14720 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 9 Meters Biopharma Inc.'s stock price $0.00 by its total outstanding shares 14459700 (14.46 Million).
9 Meters Biopharma Inc. Market Cap History: 2016 to 2024
9 Meters Biopharma Inc.'s market capitalization history from 2016 to 2024. Data shows change from $5.06 Billion to $1.45K (-83.68% CAGR).
9 Meters Biopharma Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 9 Meters Biopharma Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NMTRQ by Market Capitalization
Companies near 9 Meters Biopharma Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to 9 Meters Biopharma Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
9 Meters Biopharma Inc. Historical Marketcap From 2016 to 2024
Between 2016 and today, 9 Meters Biopharma Inc.'s market cap moved from $5.06 Billion to $ 1.45K, with a yearly change of -83.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | $1.45K | 0.00% |
| 2023 | $1.45K | -99.99% |
| 2022 | $18.22 Million | -93.56% |
| 2021 | $283.03 Million | +13.93% |
| 2020 | $248.42 Million | +54.19% |
| 2019 | $161.11 Million | -75.88% |
| 2018 | $668.04 Million | -62.13% |
| 2017 | $1.76 Billion | -65.14% |
| 2016 | $5.06 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 5th, 2025 the market cap of 9 Meters Biopharma Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.45K USD |
| MoneyControl | $1.45K USD |
| MarketWatch | $1.45K USD |
| marketcap.company | $1.45K USD |
| Reuters | $1.45K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.